Katharine Knobil has been appointed chief medical officer and head of research and development of Kaleido Biosciences. Knobil joins Lexington, MA-based Kaleido from GlaxoSmithKline (NYSE: [[ticker:GSK]]) where she had increasing roles of responsibility in the past 20 years, most recently as the company’s chief medical officer. Kaleido, which was founded by venture capital firm Flagship Pioneering, is developing microbiome therapies for a number of diseases.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
